Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 24;76(10):1843-1846.
doi: 10.1093/cid/ciad052.

Severe Mpox Infections in People With Uncontrolled Human Immunodeficiency Virus

Anusha Govind  1   2 , Susana M Lazarte  1   2 , Ellen Kitchell  1   2 , Jeremy Y Chow  1   2 , Carolee D Estelle  1   2 , Emma Fixsen  3 , Caitlin Helm  4 , Mamta K Jain  1   2 , Roma Mehta  5 , Trish M Perl  1   2 , Jaini M Sutaria  2   6 , Cristina Thomas  3   4 , Arturo R Dominguez  3   4 , Netanya S Utay  1   2
Affiliations

Severe Mpox Infections in People With Uncontrolled Human Immunodeficiency Virus

Anusha Govind et al. Clin Infect Dis. .

Abstract

In the current mpox outbreak, infections are usually self-limited. We describe 3 patients with uncontrolled HIV and mpox infections lasting months, causing debilitating lesions, complications, and death, despite initiating anti-mpox and antiretroviral therapy. Delayed treatment of mpox with antiviral agents may contribute to poor outcomes in severely immunocompromised patients.

Keywords: HIV; cytokine storm; death; immunocompromised; mpox.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. C. D. E. reports unpaid roles on the Board of Directors for Dallas County Medical Society and an unpaid role as an executive board member of the CV Roman Medical Society (DFW Chapter of the National Medical Association); receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV and from the Food and Drug Administration (FDA) for brincidofovir. A. G. reports receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV. J. Y. C. reports grants or contracts from Gilead Sciences for Investigator Sponsored Research unrelated to the topic of this manuscript and receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV. S. M. L. reports grants or contracts from Gilead Sciences as Site Principal Investigator for a Purpose 2 clinical trial regarding lenacapavir as pre-exposure prophylaxis (PrEP; payment to institution) and receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV. M. K. J. reports grants or contracts to the institution from Gilead Sciences, GSK/ViiV, Merck, and Janssen and receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV and from FDA for brincidofovir. E. K. reports receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV and from FDA for brincidofovir. T. M. P. reports receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV. N. S. U. reports receipt of drugs given to their institution for use in the patient from Dallas County Health and Human Services (from the CDC) for tecovirimat and VIGIV and from FDA for brincidofovir. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publication types

Substances